| 2017年 12月31日 | 2018年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 |
---|
Revenue | - | - | - | - | 1 | 0 |
---|
Cost of revenue | - | - | - | - | 1 | 4 |
---|
Sales and marketing | - | - | - | - | 9 | 19 |
---|
General and administrative | 5 | 6 | 8 | 12 | 26 | 41 |
---|
Amortization of acquired intangible assets | - | - | - | - | - | 2 |
---|
Research and development | 3 | 4 | 7 | 11 | 20 | 26 |
---|
Total operating expenses | - | - | - | - | - | 91 |
---|
Net loss from operations | -8,034,119 | -10,563,205 | -14,295,295 | -23 | -54 | -91 |
---|
Interest expense | - | - | 32,667 | 53 | - | 1 |
---|
Change in fair value - Senior Secured Convertible Notes and Senior Convertible Note | - | - | - | - | -2 | 1 |
---|
Loss on issue and offering costs - Senior Secured Convertible Note | - | - | - | - | - | 4 |
---|
Debt extinguishments loss - Senior Secured Convertible Notes | - | -1,408,296 | -1,831,316 | -6 | -4 | -5 |
---|
Debt forgiveness | - | - | - | - | 0 | - |
---|
Other income (expense), net | -1,485,150 | -7,609,617 | -2,972,836 | -13 | -2 | -12 |
---|
Loss before provision for income tax | -9,519,269 | -18,172,822 | -17,268,131 | -36 | -56 | -103 |
---|
Net loss before noncontrolling interests | - | - | -17,268,131 | -36 | -56 | -103 |
---|
Net loss attributable to the noncontrolling interests | - | -204,072 | -810,890 | -2 | -6 | -14 |
---|
Net loss attributable to PAVmed Inc. | -9,519,269 | -17,968,750 | -16,457,241 | -34 | -50 | -89 |
---|
Less: Series B Convertible Preferred Stock dividends earned | - | - | - | - | 0 | 0 |
---|
Net loss attributable to PAVmed Inc. common stockholders | -10,398,134 | -18,750,798 | -16,727,136 | -35 | -51 | -89 |
---|
Net loss per share attributable to PAVmed Inc. - basic and diluted | - | - | - | - | - | -1 |
---|
Net loss per share attributable to PAVmed Inc. common stockholders – basic and diluted | - | - | - | - | -0.65 | -1 |
---|